ClinicalTrials.gg
Sign In
RecruitingNCT05065060Updated Sep 8, 2026

Parkinson Progression Marker Initiative Online (PPMI Online)

An observational study in Parkinson Disease, sponsored by Michael J. Fox Foundation for Parkinson's Research. Recruiting at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-08.

Sponsored by Michael J. Fox Foundation for Parkinson's Research · Observational

From the registry’s dates

  • Started Jul 2021; still recruiting 5 years 3 months later.
Study type
Observational
Model
Cohort
Time perspective
Other
Enrollment
500,000
Ages
18 Years and older
Sex
All
01

Study summary

Parkinson Progression Marker Initiative Online (PPMI Online) is an observational study collecting participant reported information from people with and without Parkinson's disease (PD), for the goal of better understanding risk and predictive factors for PD.

PPMI Online is part of the broader Parkinson Progression Marker Initiative aimed at identifying markers of disease progression for use in clinical trials of therapies to reduce progression of PD disability.

Read the detailed description

PPMI is a broad program that is expanding the goals of the original PPMI study, and will include this PPMI Online protocol, as well the PPMI Clinical [NCT04477785], PPMI Remote, PPMI Digital protocols (with external regulatory oversight). All participants in PPMI may be asked to participate in one or all of these protocols and their enrollment in these studies may occur in varying order. PPMI participants may also be asked to participate in additional PPMI companion studies (as they are developed), which may only involve a subset of PPMI participants based on their cohort designation

02

Conditions studied

  • Parkinson Disease

Keywords

  • Parkinson
  • Neurodegenerative Disorder
  • Prodromal
  • At Risk
  • Participant Reported Outcomes
03

In context

Parkinson Disease

4,573 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.

This study's planned enrollment of 500,000 is above the median of 96 across 1,085 observational studies indexed under Parkinson Disease.

Browse Parkinson Disease studies →

Lead sponsor

Michael J. Fox Foundation for Parkinson's Research is the lead sponsor of 16 studies on the registry; 7 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

In PPMI Online, up to 500,000 participants with and without PD will be enrolled and contribute data longitudinally and cross-sectionally using a web-based platform.

Eligibility criteria

Inclusion Criteria:

  • Parkinson Disease (PD) Participants:

    • Male or female age 18 years or older.
    • Has received a diagnosis of Parkinson's disease

Participants without PD:

  • Male or female age 18 years or older.
  • Has not received a diagnosis of Parkinson's disease
05

Study design

Observational model
Cohort
Time perspective
Other
Enrollment
500,000 participants (estimated)
Patient registry
No

Interventions

  • OtherObservation

    Observation

06

What researchers measure

Primary outcomes

  1. Unified Parkinson's Disease Rating Scale Ib & II

    Evaluates self-reported motor and nonmotor Parkinson's disease symptoms

    Time frame: Baseline to 240 months

07

Study locations

1 of 1 sites recruiting
  • UCSF Movement Disorders and Neuromodulation Center (MDNC)
    San Francisco, California 94143, United States
    Recruiting
    • UCSF · Contact877-525-7764
08

References and documents

Publications

  • Pierz KA, Aamodt W, Gochanour C, Kurth R, Brumm MC, Coffey CS, Heathers LE, Totten M, Doty RL, Marek K, Siderowf A; Parkinson's Progression Markers Initiative. Percentile scores for the revised University of Pennsylvania Smell Identification Test for 16,972 individuals 60 years of age and older. NPJ Parkinsons Dis. 2025 Oct 1;11(1):280. doi: 10.1038/s41531-025-01095-9. PubMed 41034300 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2021 (actual). Primary completion is estimated for Dec 2041, 245 months after the start.

Of 378 non-industry observational studies under Parkinson Disease, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 133. This study's planned 245 months is above that.

Counting every sponsor, half of 438 studies reached it within 47 months; a quarter within 22 and three quarters within 114.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 2, 2021
First posted
Oct 1, 2021
StartActual
Jul 28, 2021
Primary completionEst.
Dec 2041
CompletionEst.
Dec 2041
Last update
Sep 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05065060
Lead sponsor
Michael J. Fox Foundation for Parkinson's Research
Responsible party
Caroline M Tanner (Protocol Co- Principal Investigator, University of California, San Francisco) — Principal investigator
First posted
Oct 1, 2021
Start date
Jul 28, 2021
Primary completion
Dec 2041 (estimated)
Completion
Dec 2041 (estimated)
Last update
Sep 8, 2026

Study contacts

University of California, San Francisco
Contact
info@ppmionline.org
877-525-7764
Caroline Tanner, MD, PhD
principal investigator · University of California, San Francisco
Kenneth L Marek, MD
principal investigator · Institute for Neurodegenerative Disorders

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Parkinson Disease →

Other studies from this sponsor

Michael J. Fox Foundation for Parkinson's Research

Start the discussion